- Home
- IMCR vs TRMK Comparison
IMCR vs TRMK Comparison
Compare IMCR & TRMK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- TRMK
- Stock Information
- Founded
- IMCR 2008
- TRMK 1889
- Country
- IMCR United Kingdom
- TRMK United States
- Employees
- IMCR N/A
- TRMK N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- TRMK Major Banks
- Sector
- IMCR Health Care
- TRMK Finance
- Exchange
- IMCR Nasdaq
- TRMK Nasdaq
- Market Cap
- IMCR 1.8B
- TRMK 2.4B
- IPO Year
- IMCR 2021
- TRMK 1987
- Fundamental
- Price
- IMCR $34.51
- TRMK $40.01
- Analyst Decision
- IMCR Buy
- TRMK Buy
- Analyst Count
- IMCR 8
- TRMK 4
- Target Price
- IMCR $57.00
- TRMK $41.00
- AVG Volume (30 Days)
- IMCR 281.5K
- TRMK 243.2K
- Earning Date
- IMCR 11-05-2025
- TRMK 10-21-2025
- Dividend Yield
- IMCR N/A
- TRMK 2.39%
- EPS Growth
- IMCR N/A
- TRMK 17.82
- EPS
- IMCR N/A
- TRMK 3.56
- Revenue
- IMCR $356,145,000.00
- TRMK $758,379,000.00
- Revenue This Year
- IMCR $31.83
- TRMK $58.78
- Revenue Next Year
- IMCR $8.50
- TRMK $4.52
- P/E Ratio
- IMCR N/A
- TRMK $11.29
- Revenue Growth
- IMCR 26.78
- TRMK 58.50
- 52 Week Low
- IMCR $23.15
- TRMK $29.77
- 52 Week High
- IMCR $39.33
- TRMK $41.34
- Technical
- Relative Strength Index (RSI)
- IMCR 51.26
- TRMK 55.54
- Support Level
- IMCR $35.33
- TRMK $39.80
- Resistance Level
- IMCR $36.76
- TRMK $40.47
- Average True Range (ATR)
- IMCR 1.34
- TRMK 0.64
- MACD
- IMCR 0.16
- TRMK -0.10
- Stochastic Oscillator
- IMCR 41.89
- TRMK 25.28
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About TRMK Trustmark Corporation
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.